Category Archives: Induced Pluripotent Stem Cells


Stem Cell Clinic > Induced Pluripotent Stem Cells

Cellectar Biosciences to Present at the 37th Annual Roth Conference

By Induced Pluripotent Stem Cells

FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:

Read the original post:
Cellectar Biosciences to Present at the 37th Annual Roth Conference

Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th

By Induced Pluripotent Stem Cells

NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the iAccess Alpha Virtual Best Ideas Spring Conference 2025 on March 25 and 26, 2025.

Go here to see the original:
Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s…

By Induced Pluripotent Stem Cells

MIAMI, March 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the publication in Nature Medicine of results from the CLEAR MIND Phase 2a clinical trial evaluating laromestrocel (Lomecel-B™) as a potential cellular therapy for mild Alzheimer’s disease (AD). The article is also available online here. The International Nonproprietary Names (INN) Expert Committee of the World Health Organization recently approved “laromestrocel” for the non-proprietary name of Lomecel-B™.

More here:
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s...

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its…

By Induced Pluripotent Stem Cells

• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities.

Read the original:
Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its...

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being…

By Induced Pluripotent Stem Cells

LONDON, March 11, 2025 (GLOBE NEWSWIRE) -- Kaerus Bioscience (www.kaerusbio.com), a clinical-stage biopharmaceutical company created by Medicxi for the development of therapeutics for rare genetic syndromes of neurodevelopment, today announces the successful completion of its Phase 1 clinical trial of KER-0193, a novel BK channel modulator the company is developing for Fragile X syndrome (FXS) and other neurodevelopmental conditions.

Go here to see the original:
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being...

GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule

By Induced Pluripotent Stem Cells

LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it received notice on March 10, 2025 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with Nasdaq Listing Rule 5550(a)(2), also known as the “minimum bid price rule.”

Visit link:
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

By Induced Pluripotent Stem Cells

ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced results for the quarter and full year ended December 31, 2024, and provided an overview of the Company’s progress.

Read the original post:
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

By Induced Pluripotent Stem Cells

LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will present new preclinical data demonstrating efficacy and safety of ETX-148 in murine models of haemophilia A and B at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), 4th-7th February 2025. ETX-148 is being developed for the treatment of bleeding disorders and is currently progressing through IND-enabling studies, with an IND submission anticipated during 2026.

See the original post here:
e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

→←